Continuation of Immunotherapy Beyond Progression is Beneficial to the Survival of Advanced Non-small-cell Lung Cancer

Overview

Journal Clin Transl Oncol

Specialty Oncology

Date 2023 Dec 25

PMID 38145428

Authors

Yuanyuan Cheng

Zhe Ye

Yanru Xie

Xuedan Du

Siqi Song

Xiaobo Ding

Chuchu Lin

Bin Wang

Wenfeng Li

Chunhong Zhang

Affiliations

Soon will be listed here.

Abstract

Purpose: To investigate the potential clinical importance of continuing immunotherapy beyond progression in patients with advanced non-small-cell lung cancer (aNSCLC).

Methods: The data of patients with aNSCLC who experienced progressive disease after receiving first-line immunotherapy plus chemotherapy were collected from multiple centers for the period from January 1, 2018 to May 31, 2022. According to the second-line treatment, the patients were classified into two groups: the continuation of immunotherapy beyond progression (CIBP) group and the discontinuation of immunotherapy beyond progression (DIBP) group. The efficacy and safety of the treatment were compared between the groups.

Results: Overall, data from 169 patients were analyzed; 93 patients were enrolled in the CIBP group and 76 patients were in the DIBP group. The median second-line progression-free survival was 5.5 months in the CIBP group, which for the DIBP group was 3.4 (p = 0.011). The median overall survival of the CIBP group was 13.3 months, whereas that of the DIBP group was 8.8 months (p = 0.031). The disease control rate of the CIBP group (79.57%) was observably higher than that of the DIBP group (64.47%; p = 0.028). Among patients who responded better (complete or partial response) to prior therapy, the median progression-free survival was 5.5 months and 3.3 months in the CIBP and DIBP groups respectively (p = 0.022), and the median overall survival was 14.8 months and 8.8 months in the CIBP and DIBP groups respectively (p = 0.046).

Conclusions: Continuing immunotherapy as a second-line treatment could be beneficial to the survival of patients with aNSCLC with disease progression beyond initial chemotherapy combined with immunotherapy.

Citing Articles

Continuous immunotherapy beyond disease progression in patients with advanced non-small cell and small cell lung cancer.

Cheng J, Kang W, Chen Y, Pan L, Han H, Lv T Cancer Immunol Immunother. 2025; 74(4):124.

PMID: 39998635 PMC: 11861770. DOI: 10.1007/s00262-025-03958-9.

Crosstalk between non-coding RNAs and programmed cell death in colorectal cancer: implications for targeted therapy.

Taha S, Karimi M, Mahdavi B, Yousefi Tehrani M, Bemani A, Kabirian S Epigenetics Chromatin. 2025; 18(1):3.

PMID: 39810224 PMC: 11734566. DOI: 10.1186/s13072-024-00560-8.

Continuation of same programmed death-1 inhibitor regime beyond progression is a novel option for advanced gastric cancer.

Li J, Ding F, Zhang S, Jia Y, Zhang T, Wang S BMC Cancer. 2024; 24(1):1292.

PMID: 39425079 PMC: 11490043. DOI: 10.1186/s12885-024-13063-2.

Comparative transcriptome analysis of doramectin-producing Streptomyces avermitilis N72 and its mutant strains.

Pan X, Cai J World J Microbiol Biotechnol. 2024; 40(7):228.

PMID: 38822927 DOI: 10.1007/s11274-024-04028-5.

References

Chen W, Zheng R, Baade P, Zhang S, Zeng H, Bray F . Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66(2):115-32. DOI: 10.3322/caac.21338. View

Ge X, Zhang Z, Zhang S, Yuan F, Zhang F, Yan X . Immunotherapy beyond progression in patients with advanced non-small cell lung cancer. Transl Lung Cancer Res. 2021; 9(6):2391-2400. PMC: 7815351. DOI: 10.21037/tlcr-20-1252. View

Dolly S, Collins D, Sundar R, Popat S, Yap T . Advances in the Development of Molecularly Targeted Agents in Non-Small-Cell Lung Cancer. Drugs. 2017; 77(8):813-827. DOI: 10.1007/s40265-017-0732-2. View

Shepherd F, Dancey J, Ramlau R, Mattson K, Gralla R, ORourke M . Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol. 2000; 18(10):2095-103. DOI: 10.1200/JCO.2000.18.10.2095. View

Metro G, Addeo A, Signorelli D, Gili A, Economopoulou P, Roila F . Outcomes from salvage chemotherapy or pembrolizumab beyond progression with or without local ablative therapies for advanced non-small cell lung cancers with PD-L1 ≥50% who progress on first-line immunotherapy: real-world data from a European.... J Thorac Dis. 2020; 11(12):4972-4981. PMC: 6988053. DOI: 10.21037/jtd.2019.12.23. View

Tian T, Yu M, Yu Y, Wang K, Tian P, Luo Z . Immune checkpoint inhibitor (ICI)-based treatment beyond progression with prior immunotherapy in patients with stage IV non-small cell lung cancer: a retrospective study. Transl Lung Cancer Res. 2022; 11(6):1027-1037. PMC: 9271428. DOI: 10.21037/tlcr-22-376. View

Li L, Liu T, Liu Q, Mu S, Tao H, Yang X . Rechallenge of immunotherapy beyond progression in patients with extensive-stage small-cell lung cancer. Front Pharmacol. 2022; 13:967559. PMC: 9485935. DOI: 10.3389/fphar.2022.967559. View

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

Mandaliya H, Jones M, Oldmeadow C, Nordman I . Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2020; 8(6):886-894. PMC: 6976360. DOI: 10.21037/tlcr.2019.11.16. View

10.

Yu Q, Du X, Fang Z, Mao X, Wu J, Wang B . Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer. Cancer Manag Res. 2021; 13:8651-8661. PMC: 8608410. DOI: 10.2147/CMAR.S337830. View

11.

Camp R, Dolled-Filhart M, Rimm D . X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004; 10(21):7252-9. DOI: 10.1158/1078-0432.CCR-04-0713. View

12.

Li N, Yang L, Ou W, Zhang L, Zhang S, Wang S . Meta-analysis of EGFR tyrosine kinase inhibitors compared with chemotherapy as second-line treatment in pretreated advanced non-small cell lung cancer. PLoS One. 2014; 9(7):e102777. PMC: 4100920. DOI: 10.1371/journal.pone.0102777. View

13.

Kawaguchi T, Ando M, Asami K, Okano Y, Fukuda M, Nakagawa H . Randomized phase III trial of erlotinib versus docetaxel as second- or third-line therapy in patients with advanced non-small-cell lung cancer: Docetaxel and Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol. 2014; 32(18):1902-8. DOI: 10.1200/JCO.2013.52.4694. View

14.

Gandara D, von Pawel J, Mazieres J, Sullivan R, Helland A, Han J . Atezolizumab Treatment Beyond Progression in Advanced NSCLC: Results From the Randomized, Phase III OAK Study. J Thorac Oncol. 2018; 13(12):1906-1918. DOI: 10.1016/j.jtho.2018.08.2027. View

15.

Ziolkowska B, Cybulska-Stopa B, Papantoniou D, Suwinski R . Systemic treatment in patients with malignant pleural mesothelioma - real life experience. BMC Cancer. 2022; 22(1):432. PMC: 9022247. DOI: 10.1186/s12885-022-09490-8. View

16.

Ricciuti B, Genova C, Bassanelli M, De Giglio A, Brambilla M, Metro G . Safety and Efficacy of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer Treated Beyond Progression. Clin Lung Cancer. 2019; 20(3):178-185.e2. DOI: 10.1016/j.cllc.2019.02.001. View

17.

Brahmer J, Drake C, Wollner I, Powderly J, Picus J, Sharfman W . Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J Clin Oncol. 2010; 28(19):3167-75. PMC: 4834717. DOI: 10.1200/JCO.2009.26.7609. View

18.

Giaj Levra M, Cotte F, Corre R, Calvet C, Gaudin A, Penrod J . Immunotherapy rechallenge after nivolumab treatment in advanced non-small cell lung cancer in the real-world setting: A national data base analysis. Lung Cancer. 2020; 140:99-106. DOI: 10.1016/j.lungcan.2019.12.017. View

19.

Pallis A, Agelaki S, Agelidou A, Varthalitis I, Syrigos K, Kentepozidis N . A randomized phase III study of the docetaxel/carboplatin combination versus docetaxel single-agent as second line treatment for patients with advanced/metastatic non-small cell lung cancer. BMC Cancer. 2010; 10:633. PMC: 2994826. DOI: 10.1186/1471-2407-10-633. View

20.

Herbst R, Sun Y, Eberhardt W, Germonpre P, Saijo N, Zhou C . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010; 11(7):619-26. PMC: 3225192. DOI: 10.1016/S1470-2045(10)70132-7. View